R&D

R&D
GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia

GEXVal Inc.July 1, 2024 GEXVal Completes Phase I Clinical Trial of GXV-001 in Australia We are pleased to anno […]

Read more
R&D
GEXVal Sponsors SLTBR 2024 35th Annual Meeting

GEXVal Inc.June 18, 2024 GEXVal Sponsors SLTBR 2024 35th Annual Meeting GEXVal Inc. is proud to sponsor the 35 […]

Read more
R&D
GEXVal Inc. Announces Collaboration with FRAXA-DVI

GEXVal Inc.February 28, 2023 GEXVal Inc. is pleased to announce that we have initiated a collaboration project […]

Read more
R&D
Phase 1 Study of GXV-001 in Australia: Start of Repeated-Dose Study

  GEXVal Inc.February 15, 2023 Phase 1 Study of GXV-001 in Australia: Start of Repeated-Dose Study GEXVal Inc. […]

Read more
R&D
Initiation of Basic Research for Drug Repurposing Utilizing Fugaku

GEXVal Inc.January 20, 2023 GEXVal Inc. (hereinafter "GEXVal") has started research on AI (Artificial Intellig […]

Read more